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as fixed effects and baseline value as covariate. The model was chosen in accord-
ance with the pre-specified model for the clinical trial. Results: SF-36 estimated 
treatment differences (ETD; IDegLira–IGlar), at EOT were 1.9 points [95% CI: 0.8; 3.1] 
(p< 0.001) and –0.1 points [95% CI: –1.5; 1.3] (NS) for physical and mental component 
summary scores, respectively. Mean EQ-5D score ± SD at baseline was 0.901 ± 0.083. 
At EOT mean EQ-5D score ± SD was 0.915 ± 0.070 and 0.903 ± 0.084 for IDegLira and 
IGlar, respectively; ETD 0.017 points [95% CI: 0.007; 0.026] (p= 0.001). ConClusions: 
This analysis suggests that IDegLira provides a statistically significant improvement 
in health utility compared with IGlar, in patients with T2D inadequately controlled 
on IGlar and metformin. The health utility improvement was generally driven by 
improvement in physical health, while mental health remained stable.
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objeCtives: Data on wastage behaviours of patients with diabetes taking mealtime 
insulin (MTI) with a prefilled disposable pen or reusable pen with disposable car-
tridge are lacking. A patient survey was undertaken to estimate the average number 
of MTI units discarded per pen/cartridge by patients with diabetes taking > 20 units/
day, based on injection habits when insufficient insulin remains in a pen/cartridge 
to administer a full dose in a single injection. Methods: Cross-sectional, online, 
self-reported survey of MTI usage and wastage behaviours in adults with type 1 or 
2 diabetes [T1D, T2D] using > 20 units/day of MTI administered via 100 units/mL 
pen/cartridge for ≥ 1 month, conducted between February and March 2015 in four 
EU countries [France, Germany, Italy, United Kingdom]. Results: 400 patients with 
diabetes [120 T1D; 280 T2D] completed the survey. Mean age (SD) was 54.5 (12.2) years 
[T1D: 50.3 (13.0); T2D: 56.3 (11.4)]. Average BMI was 29.9 (7.2) kg/m2 [T1D: 26.9 (4.9); 
T2D: 31.3 (7.7)]. Average time since diabetes diagnosis was 16.1 (11.7) years [T1D: 23.4 
(14.2); T2D: 13.0 (8.8)]. Total average MTI units taken per day (self-reported number 
of units taken at breakfast, lunch and dinner combined) was 54.8 (34.1) units [T1D: 
41.1 (21.9); T2D: 60.6 (36.7)]. 255 patients [63.8%] reported wasting no insulin, whereas 
145 patients [36.3%] reported wasting some insulin. Overall, patients reported dis-
carding 2.0 [95% CI 1.4–2.5] pens/cartridges per month on average that still had 
insulin remaining. Patients who reported wasting some insulin discarded on average 
8.6 [95% CI 7.2–10.0] units of MTI per pen/cartridge. ConClusions: One third of 
patients taking > 20 units/day MTI reported discarding at least one 100 units/mL pen/
cartridge with insulin remaining. These results suggest there may be an opportunity 
to reduce insulin wastage with new higher strength MTI formulations that provide 
more total units per pen and fewer pen/cartridge transitions.
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objeCtives: To investigate the frequency of hypoglycaemic episodes and its effect 
on diabetes management, healthcare resource use, economic burden and time loss 
(including time loss from work and daily life) for insulin-treated diabetes patients in 
urban China. Methods: A questionnaire was used to collect data from 7 third-grade 
class-A hospitals in Beijing, Nanjing, Chengdu, Kunming and Ha’erbin in China from 
July to September of 2012. Type 1 and type 2 diabetes patients treated with insulin 
were included. Hypoglycaemia episodes were categorized as mild (symptoms could 
be self-disappeared), moderate (symptoms could not be self-disappeared), severe 
(coma happen, usually require medical assistance) and nocturnal (occur during 
sleep, including mild, moderate and severe) hypoglycaemia. Descriptive Statistic 
analysis was applied to the data. Results: More than half (56.7%) of 602 enrolled 
patients reported experiencing hypoglycaemia. 34.7%, 3.3% and 3.5% patients 
reported mild, moderate and nocturnal hypoglycaemia during the preceding month, 
with a total of 593, 84.5 and 45.5 episodes, respectively. 9 patients reported 12 severe 
hypoglycaemia episodes during the preceding year. Among patients experiencing 
hypoglycaemia, 15.5% reported anxiety of anti-diabetes drugs, 16.1% reported 
treatment regimens modification by themselves and 12.6% by their doctors, 19.9% 
reported extra self-monitoring of blood glucose of 3.14 times/week, 11.7% reported 
time loss by an average of 2 days/event, and 9.4% reported time loss for family 
members by an average of 1.89 days/event. Of the patients experiencing severe 
hypoglycaemia, 28.6% required emergency visit and 14.3% required hospitalization. 
Of patients experiencing nocturnal hypoglycaemia, 5.3% required hospitalization. 
Patients experiencing hypoglycaemia reported an average of hypoglycaemia-related 
cost of 44.06CNY/month. Nevertheless, for those who required medical assistance, 
the medical cost was 1216.53 CNY/event. ConClusions: Hypoglycaemia was com-
mon in diabetes patients treated with insulin. Hypoglycaemia had negative impact 
on diabetes management and was associated with increasing healthcare utilization, 
economic burden and time loss for patients and family.
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objeCtives: An adequate disease-related knowledge is important in treatment 
and management of ailments. Within this context, patients are needed to have 
for a better control of diabetes. ConClusions: The responses of patients with 
both types of diabetes clearly show the need for new management approaches 
to alleviate the burden associated with the disease addressing the specific unmet 
needs of diabetic patients.
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objeCtives: To use a discrete choice experiment (DCE) to evaluate preferences for 
the actual treatment features and overall profiles of two injectable glucagon-like 
peptide-1 (GLP-1) receptor agonists (dulaglutide and liraglutide) among patients 
with type 2 diabetes (T2DM) in the United Kingdom (UK). Methods: In-person 
interviews were conducted in the UK to administer a DCE to patients with self-
reported T2DM, naïve to treatment with injectable medications. The DCE examined 
6 attributes of T2DM treatment each described by 2 levels: ‘dosing frequency,’ ‘HbA1c 
change,’ ‘weight change,’ ‘type of delivery system,’ ‘frequency of nausea,’ and ‘fre-
quency of hypoglycemia.’ Part-worth utilities were estimated using random effects 
logit models and used to calculate relative importance values for each attribute. A 
Chi-square test was used to determine differences in preferences for dulaglutide vs. 
liraglutide profiles. Results: A total of 243 participants [mean age: 60.5 (SD 10.9) 
years; 76.1% male; mean BMI: 29.8 (SD 5.4) kg/m2] completed the study. Relative 
importance values for the attributes in rank order were: ‘dosing frequency’ (41.6%), 
‘type of delivery system’ (35.5%), ‘frequency of nausea’ (10.4%), ‘weight change’ 
(5.9%), ‘HbA1c change’ (3.6%), and ‘frequency of hypoglycemia’ (3.0%). Significantly 
more participants preferred the dulaglutide profile (83.1%) compared to the liraglu-
tide profile (16.9%; p< 0.0001). ConClusions: This study elicited patients’ prefer-
ences for attributes and levels representing the actual characteristics of two specific 
GLP-1 medications. In this context, dosing frequency and type of delivery system 
were most important, accounting for over 75% of the relative importance. While 
previous studies have identified efficacy as highly important in T2DM medication 
decisions, this study suggests that when differences in efficacy between medica-
tions are small, other treatment features (e.g., dosing frequency and delivery system) 
are of much greater importance to patients.
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objeCtives: Understanding the preferences for attributes of T2DM treatments 
among patients in Spain. Methods: Patients in Spain (self-reported physician 
diagnosis of T2DM, taking a prescription T2DM medication for > 2 years) com-
pleted an online discrete-choice experiment (DCE) survey (funded by GSK) to elicit 
preferences for T2DM treatment attributes. Respondents chose between pairs 
of hypothetical T2DM treatments defined by seven attributes: chance of reach-
ing target HbA1c, reduction in risk of serious heart attack or stroke, frequency 
of hypoglycemia, risk of gastrointestinal (GI) problems, weight change, mode of 
administration, and dosing frequency. Random-parameters logit (RPL) was used 
to analyze the data. Minimum acceptable benefit (MAB) was calculated with RPL 
coefficients and measures the percentage point (pp) increase in the probability of 
reaching target HbA1c that respondents require in order to accept worse levels of 
other attributes. Results: 401 patients responded (mean age 51, 77% male, 33% 
diagnosed more than 7 years ago). The DCE respondents preferred pills to injections 
and once-weekly dosing over other schedules. The highest MAB levels were: moving 
from pill to injection (MAB= 59pp), moving from once-weekly dosing frequency to 
more than twice a day (MAB= 40pp), moving from no risk of GI problems to 30% risk 
of GI problems (MAB= 37pp), moving from no hypos to more than 2 hypos per month 
(MAB= 37pp), and moving from a 2-kg weight loss to a 2-kg weight gain (MAB= 35pp). 
Respondents using injectables were indifferent between pills and injections, while 
respondents not using injectables had a strong preference for pills over injections 
(P = 0.00). ConClusions: Respondents were willing to trade-off efficacy for an 
improvement in mode of administration (from injection to pills) and improved side 
effects . Given the variety of T2DM medications available, the results suggest that 
careful discussion about patient preferences could help improve patient satisfac-
tion with T2DM drugs.
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objeCtives: This analysis of data from the DUAL V clinical trial compared health 
utility scores of IDegLira, a fixed-ratio combination of insulin degludec and liraglu-
tide, with insulin glargine (IGlar) in patients with type 2 diabetes (T2D). Methods: 
Health status data were collected using the Short-Form 36 v2 (SF-36) questionnaire 
during a 26-week, multinational, multi-centre, open-label, parallel, randomised, 
treat-to-target trial comparing IDegLira (n= 278) with IGlar (n= 279) (either treat-
ment given once daily in addition to metformin) in patients with T2D, inadequately 
controlled on IGlar (20–50 units daily) and metformin (Buse et al. Diabetes 2015; 64 
(Suppl. 1):A43–A44; abstract 166-OR). In this post hoc analysis, SF-36 scores were 
mapped to the EuroQol-5D (EQ-5D) health utility scale using a validated algorithm 
(Model 3; Rowen et al. Health Qual Life Outcomes 2009;7:27). EQ-5D scores at end 
of trial (EOT) were analysed using an ANCOVA model with treatment and region 
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objeCtives: The approach of the diabetes register named DIAREG is to display the 
health care reality of patients with type 2 diabetes (T2D) in Germany. In comparison 
to other existing diabetes registries, DIAREG analyses patient-reported outcomes 
(PRO) in order to illustrate patient reported quality of life (QoL). Methods: In July 
2013 DIAREG was started including retrospective as well as prospective data from 
over 100 office based physicians (general practitioner and diabetologists). DIAREG 
analysis is based on 6 different PRO: generic quality of life questionnaire (SF-36); 
audit of diabetes–dependent quality of life (ADDQoL); diabetes treatment satisfac-
tion questionnaire (DTSQ); impact of weight quality of life (IWQoL-Lite); Center of 
Epidemiological Studies Depression Scale (CES-D) and WHO five well being index 
(WHO-5). Results: By June 2015 more than 2,000 T2D patients were included in the 
register, involving an observation period of 22 months. Within this time frame PRO 
of more than 300 patients were completed. The mean age of T2D patients was 68.5 
years, whereas 48% of the patient population was older than 70 years. According to 
a subgroup analysis of 1,646 patients, 16% of the patients were recruited by office-
based diabetologists and the majority of 84% by primary care physicians. About 20% 
of these patients had their therapy changed within the last year due to inadequate 
HbA1C control. An adjustment of the current therapy was conducted at 81%, a 
change of the therapy at 46%. Main focus of the physicians for changing the therapy 
pattern was the decrease of the HbA1C. Based on this platform, further evaluation 
on QoL will be started. ConClusions: In conclusion, DIAREG shows the treatment 
reality from the patient and physician perspective and will therefore describe the 
health care situation and QoL of diabetes patients in Germany.
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objeCtives: To develop a specific questionnaire to assess the impact of hypo-
glycemia on the health-related quality of life (HRQoL) of patients with type 2 dia-
betes mellitus (T2DM). Methods: A first version of the QolHypo questionnaire 
was obtained from a literature review and focus groups with patients and physi-
cians. QolHypo consisted of 37 specific items about the impact of hypoglycemia on 
HRQoL with 5 response categories. The final version was obtained by item reduction 
methods: floor and ceiling effects and Rasch analysis. Rasch methodology allowed 
obtaining a questionnaire which responses will be a trade-off between respondent’s 
abilities and item difficulty. Rasch assesses the appropriateness of item responses 
with probability curves that must appear ordered as the response categories. 
Overlapped categories suggested excess of response options and were reduced and 
items with disordered categories were eliminated. The goodness of fit of items in the 
Rasch model was calculated using the normalized Infit and Outfit statistics whose 
interval of good fit is (-2, 2). Items with statistics falling outside that interval were 
removed. Analyses were performed on a sample of 140 patients. Results: 55.0% of 
patients were men, aged 63.0 (mean)(SD:9.6) years. Patients had 14.6 (mean)(SD:6.9) 
years of T2DM duration and 5.5 (mean)(SD:11.1) hypoglycemias in the previous 
6 months. 11 items were deleted because of floor and ceiling effect. Most of probabil-
ity curves showed overlapping response categories; therefore two pairs of categories 
were joined. Probability curves were represented again and 11 items that showed 
disordered categories were eliminated. Goodness of fit of the 15 remaining items 
showed only 2 items not adjusting to the model that were deleted. The final version 
of QolHypo consisted of 13 items with 3 response categories. ConClusions: Rasch 
analysis has led to obtain a reduced questionnaire for measuring how hypoglycemia 
affects the HRQoL in T2DM patients.
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objeCtives: Diabetic foot ulcer (DFU) is a common complication of diabetes and 
not only an important factor of mortality among patients with diabetes but also 
a cause of decreased quality of life. The Diabetic Foot Ulcer Scale (DFS) and short 
form of the DFS (DFS-SF) provide comprehensive measurement of the impact of 
diabetic foot ulcers on patients’ QoL. The purpose of this study was to translate 
DFS-SF into Polish and evaluate its psychometric performance in patients with 
diabetic foot ulcers. Methods: DFS-SF translation process was performed in line 
with Principles of Good Practice for the Translation and Cultural Adaptation Process 
for PROMs developed by ISPOR TCA group. Assessment of the reliability and valid-
ity of Polish DFS-SF was performed in native Polish patients with current DFU. The 
severity of ulcers was evaluated using the PEDIS scale. For each scale, the item 
convergent validity and discriminant validity was computed. Internal consistency 
of each subscale was examined using the Cronbach’s alpha coefficient. Inter-scale 
validity was examined by Spearman’s rank correlation coefficient between DFS-SF 
and SF-36v2. Results: The DFS-SF validation study involved 212 patients diagnosed 
with DFU, with 4.4 years of DFU duration on average. The average ulcer size was 
7.0 sq cm, and generally only one limb was affected. Men (72%) and type 2 diabetes 
patients (86%) prevailed, with 17.8 years representing the mean time since diagnosis. 
The mean population age was 62.5 years. The internal consistency of all scales of the 
Polish DFS-SF was high (Cronbach’s alpha ranged from 0.83 to 0.94). Item convergent 
and discriminant validity was satisfactory (median corrected item-scale correlation 
ranged from 0.61 to 0.81). The Polish DFS-SF demonstrated good construct validity 
when correlated with the SF-36v2. ConClusions: The newly translated Polish 
DFS-SF may be used to assess the impact of DFU on HRQoL in Polish patients.
correct knowledge and positive attitude especially when they are faced with an 
emergence of chronic diseases. The aim of this study therefore is to assess the 
level of Type 2 Diabetes Mellitus (T2DM) awareness and disease related attitude 
among general population at Bujang Valley, Merbok, Kedah, Malaysia. Methods: 
A questionnaire based, cross sectional study was conducted. The Diabetes Attitude 
Scale was used to assess the knowledge and attitude of respondents towards 
T2DM. Data was described descriptively and SPSS v.22 was used for data analy-
sis. Results: Out of three hundred and seventy seven respondents, major-
ity of the respondents (n= 156, 41.4%) were in age group of more than 40 years 
old and the cohort was dominated by Malay ethnic group. Females subjugated 
over males (n= 229, 60.7%) and the highest number of respondents were work-
ing as businessman (n= 115, 30.5%). Corresponding to the marital status, major-
ity of the respondent were married (n= 247, 65.5%). Majority of the respondents 
(n= 274, 72.7%) were reported as healthy with no chronic disease. The respond-
ents reported certain misapprehensions where they believed that T2DM have 
lesser complications, blood glucose control is needed for Type 1 Diabetes Mellitus 
only and the emotional effects of T2DM are minor. ConClusions: The study 
reported insufficient level of knowledge among the respondents in management 
of T2DM. General population needs to have good collaboration with healthcare 
professionals to get more education and knowledge related to T2DM for their 
empowerment.
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objeCtives: A small but growing body of evidence suggests that acute post-prandial 
hyperglycaemia (PPHG) can have a significant impact on some people with diabetes. 
This study was designed to develop a standardised tool to measure the impact of 
PPHG episodes. Methods: Twenty-four adults (≥ 18 yrs) with Type 1 (n= 14) and 
Type 2 (n= 10) insulin-dependent diabetes took part in a qualitative study to describe 
the experience and impact of PPHG. Data were collected via one-to-one telephone 
interviews in the US (n= 10) and two focus groups in the UK (n= 14). Thematic analy-
sis was conducted on the transcripts to identify emerging themes. Themes were 
drawn into measurement domains and described in terms of specific items. The 
study protocol was approved by an ethics review board. Results: The qualita-
tive analysis identified 7 clear domains which could be grouped into two larger 
groups. The first 4 domains (25 items) relate to participants’ most recent spike 
in blood sugar within the last 2 weeks (How I felt; Thinking and Concentration; 
Work; Awareness). The remaining 3 domains (22 items) relate more generally to 
the experience of PPHG after eating (Preventative Behaviours; Worry and Concerns; 
Management). ConClusions: The qualitative research identified a range of dif-
ferent ways that people can be affected by acute PPHG. This is reflected in the 
domains of the new measure. Further validation and testing is required and this 
is planned in a quantitative study involving 800 participants in the UK and US. 
This measure, when finalised, will allow us to better understand the impact and 
burden of acute PPHG.
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objeCtives: Patient-reported outcomes is an effective way to evaluate risks/ben-
efits of antidiabetic treatment in patients with T2DM and has been increasingly 
considered in treatment decision-making. The goal of this multicenter observa-
tional study was to evaluate quality of life (QoL) and hypoglycemia burden in T2DM 
patients receiving oral combination therapy in a real-world setting. Methods: A 
total of 160 T2DM patients receiving vildagliptin plus metformin (mean age 59.6 yrs; 
male/female 25/57) or sulphonylureas (SU) plus metformin (mean age 65.1 yrs; male/
female 23/55) for at least 6 months (mean 6.5 yrs, 0.6–17 yrs) were enrolled in the 
study. All the patients completed the QoL questionnaire SF-36 and the Hypoglycemia 
Perspectives Questionnaire. Integral QoL Index (IQoLI) was calculated on the basis 
of SF-36. Group comparisons were made using χ 2 test and analysis of covariance 
(ANCOVA) with adjustment for age, sex, disease duration, HbA1c level, complica-
tions, comorbidities. Results: Patients receiving SU plus metformin had worse 
role physical and role emotional functioning, vitality, social functioning and pain 
(p< 0.01) than those receiving vildagliptin plus metformin; their IQoLI was signifi-
cantly lower than in the latter group (p< 0.05). They exhibited more pronounced QoL 
impairment as compared to those receiving vildagliptin plus metformin (p= 0.002). 
50% patients on SU plus metformin vs 27% patients on vildagliptin plus metformin 
experienced hypoglycemia during the last 6 months (p< 0.003). In the group on SU 
plus metformin 9.6% patients had severe hypoglycemia and 4.1% – nocturnal hypo-
glycemia; patients on vildagliptin plus metformin – only non-severe hypoglycemia 
and no nocturnal hypoglycemia episodes. SU plus metformin therapy was accom-
panied with pronounced hypoglycemia burden as compared to vildagliptin plus 
metformin therapy. ConClusions: Results of this real-world study demonstrate 
benefits of vildagliptin plus metformin combination therapy in T2DM patients as 
compared to SU plus metformin therapy in terms of better QoL and lower risks of 
treatment in terms of less hypoglycemia burden.
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